Reyataz and ritonavir are approved as a combination therapy for HIV-1 patients
Reyataz (atazanavir) used in combination with ritonavir wins FDA approval for treatment of HIV-1 patients.
Key Points
The U.S. Food and Drug Administration has approved the use of Reyataz (atazanavir) 300 mg once daily with ritonavir 100 mg as part of combination therapy in previously untreated HIV-1 infected patients.
Reyataz is a prescription medicine used in combination with other medicines to treat people with the HIV virus. "Bristol-Meyers Squibb is committed to developing medicines that enhance the care of people living with HIV and AIDS," Elliot Sigal, a executive vice president of Bristol-Meyers, the maker of the drug, said. "Boosted Reyataz provides healthcare professionals with a newly-approved, once-daily dosing option as part of [combo] therapy."
